Participate in Protagonist Clinical Trials
For information on clinical trials currently being conducted by Protagonist or our partners, including eligibility criteria and clinical site locations, please visit
clinicaltrials.gov
or contact
[email protected].
Drug Therapies in Clinical Studies
Rusfertide (PTG-300)
is a hepcidin mimetic currently being studied as a treatment for polycythemia vera (PV).
Icotrokinra (JNJ-2113)
is an oral peptide designed to block the IL-23 receptor, targeting inflammation in moderate-to-severe plaque psoriasis, ulcerative colitis, and other IL-23-mediated diseases.
Developed through a collaboration between Protagonist Therapeutics and Janssen Biotech (a Johnson & Johnson company), icotrokinra is in Phase 3 trials for psoriasis and psoriatic arthritis, and Phase 2b trials for ulcerative colitis. J&J retains exclusive global rights for its development and commercialization*.
*All icotrokinra trials conducted by J&J.
Learn more.
Learn More About PV and the VERIFY Clinical Study
Protagonist Therapeutics Chief Medical Officer Dr. Arturo Molina joins Talk! with Audrey to discuss the VERIFY Phase 3 clinical study, along with the common symptoms and challenges faced by PV patients. Watch the full interview to learn more.